Gsk Share Discussion Threads

[tradermichael] 23/1/2019 10:54

GlaxoSmithKline has a share of around 5% of the world's pharmaceutical market. The company employs around 99,300 people in over 100 countries. In 2010 they delivered 1.4 billion vaccine doses to 179 countries. As of today, it has a market capitalisation of £73.5 billion, the seventh largest on the London Stock Exchange.

I'm staying put ….. at least till Emma's plan materialises ;0)

P.S. I buy large quantities and sell on the swings to regularly gain small increments. That, plus the dividends covers my needs - and I always re-invest the returns.

[montyhedge] 23/1/2019 09:49

When everything digested these will be higher, seems a crazy price.

[anhar] 23/1/2019 09:44

GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (GBP4.0 billion). The transaction, which was announced on 3 December 2018, significantly strengthens GSK's pharmaceutical business, accelerating the build of GSK's pipeline and commercial capability in oncology.

That's not good news TM! They already had crippling debt levels and this big transaction, being for cash, must worsen that. It was known for some time but the news of completion is nothing to celebrate, quite the reverse. :~(

What an appalling share GSK has been for long term growth investors. Glad I'm not one :~)

[tradermichael] 23/1/2019 09:02

£1 = US$1.30

[philanderer] 22/1/2019 17:44

Nice and steady 👍

[tradermichael] 22/1/2019 16:13

GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (GBP4.0 billion). The transaction, which was announced on 3 December 2018, significantly strengthens GSK's pharmaceutical business, accelerating the build of GSK's pipeline and commercial capability in oncology.

[watfordhornet] 22/1/2019 13:05

Thanks all

[wbecki] 22/1/2019 12:57

Announcement date, Wednesday 6 February 2019.
Ex-dividend date*, Thursday 21 February 2019.
Record date, Friday 22 February 2019

Apparently.

[tradermichael] 22/1/2019 12:57

2018 Q4 Ex-dividend date

Thursday 21 February 2019

[watfordhornet] 22/1/2019 12:55

When does this go ex divi for next qtr payment. Apologies if obvious but cannot find the date

[montyhedge] 22/1/2019 12:21

Can't get pass 1500p 1499p was the best so far.

[abdullla] 22/1/2019 10:16

SP is very unstable.

[montyhedge] 22/1/2019 08:55

1500p resistance point, but if break through and hold at close, that's a great pivotal point broken. Then onwards and upwards.

[bioking] 21/1/2019 15:29

RALLYYYYYYYYYY on this undiscovered stock ....
Futura Medical (FUM)= Market cap 20 million /Cash 10.5 million / Potency Drug with 2 BILLION Market potential close to Phase 3 readout /CSD500 Condom approved in Europe and many Countries outside of Europa + more Approvals & Licensing deals coming / TPR100 (Topical Gel for Pain ) first approval expected next Quarter = POTENTIAL 10++ BAGGER GEM

Futura Medical featured in Growth Company Investor recommendations 08 January 2019

CEO James Barder describes Futura as a medtech
rather than biotech business. Its proprietary technology is
DermaSys which delivers drugs rapidly through the skin and
into the blood system. The lead product is MED2005 which
is a topical gel for erectile dysfunction. The main advantage
over Viagra is that it takes effect within five minutes, compared
with over an hour for the famous blue pills. Which ensures key
ingredients of spontaneity and mood can be retained while
the treatment works. Research suggests a 20% market share
could be possible, equating to sales of $560m in major western
markets. In time an OTC version could more than double this.

[jadeticl3] 21/1/2019 15:14

I agree with TM, but Porsche is correct in saying that this share price is very disappointing. We talk about £16 or more but it is proving very difficult to stay above £15 just now. I believe EW has a fresh outlook, which is exciting and adventurous, but as yet with no evidence to give us real confidence. But I am sticking with GSK for now.

[tradermichael] 21/1/2019 15:06

Not forgetting the value to be unlocked by Consumer Healthcare

[tradermichael] 21/1/2019 15:03

I'm happy with it. Risk is limited and potential upside is good (e.g. Shingrix, immuno-oncology). The dividend will increase with the turnaround as well. Has global market, protected by US $ earnings.

[porsche1945] 21/1/2019 14:37

what a dissapointing share to own this is, zero capital growth, people bang on about yield but you can pick up 30 pc higher yields from some income funds without the stock specific risk....Asta Z really shown these up.

[philanderer] 21/1/2019 11:51

Quiet day today , US markets closed for Martin Luther King holiday.

[montyhedge] 21/1/2019 11:03

Analyst on CNBC said pharma's place to be, thats good, I'm already there, lol.
Should have a run after the figures. 23p dividend in the bag coming.

[wbecki] 21/1/2019 09:42

Suspected as much TM.
GSK certainly is taking a significant change in direction.

[tradermichael] 21/1/2019 09:21

Focus on this: next ex-div date: Thursday 21 February 2019

[tradermichael] 21/1/2019 09:21

He's part of the 'old guard' - should think the new culture is leaving him behind